Peroxisomes are small cellular organelles that were almost ignored for years because they were believed to play only a minor role in cellular functions. However, it is now known that peroxisomes play an important role in regulating cellular proliferation and differentiation as well as in the modulation of inflammatory mediators. In addition, peroxisomes have broad effects on the metabolism of lipids, hormones, and xenobiotics. Through their effects on lipid metabolism, peroxisomes also affect cellular membranes and adipocyte formation, as well as insulin sensitivity, and peroxisomes play a role in aging and tumorigenesis through their effects on oxidative stress.
Objective:
To review genetically determined peroxisomal disorders, especially those that particularly affect the skin, and some recent information on the specific genetic defects that lead to some of these disorders. In addition, we present some of the emerging knowledge of peroxisomal proliferator activator receptors (PPARs) and how ligands for these receptors modulate different peroxisomal functions. We also present information on how the discovery of PPARs, and the broad and diverse group of ligands that activate these members of the superfamily of nuclear binding transcription factors, has led to development of new drugs that modulate the function of peroxisomes.
Conclusion:
PPAR expression and ligand modulation within the skin have shown potential uses for these ligands in a number of inflammatory cutaneous disorders, including acne vulgaris, cutaneous disorders with barrier dysfunction, cutaneous effects of aging, and poor wound healing associated with altered signal transduction, as well as for side effects induced by the metabolic dysregulation of other drugs.
Get full access to this article
View all access options for this article.
References
1.
PerichonRBourrreJMKellyJF. The role of peroxisomes in aging. Cell Mol Life Sci1998; 54:641–652.
2.
GonzalesFJPetersJMCattleyRC. Mechanism of action of the nongenotoxic peroxisome proliferators: Role of the peroxisome proliferator-activator receptor alpha. J Natl Cancer Inst1998; 90:1702–1709. DOI: 10.1093/jnci/90.22.1702
3.
WandersRJTagerJM. Lipid metabolism in peroxisomes in relation to human disease. Mol Aspects Med1998; 19:69–154.
4.
MastersCCraneD. On the role of the peroxisome in cell differentiation and carcinogenesis. Mol Cell Biochem1998; 187:85–97. DOI: 10.1023/A:1006863123068
5.
BieriF. Peroxisome proliferators and cellular signaling pathways: A review. Biol Cell1993; 77:43–44.
6.
MastersCCraneD. On the role of the peroxisome in cell differentiation and carcinogenesis. Mol Cell Biochem1998; 187:85–97 DOI: 10.1023/A:1006863123068
7.
MastersCJ. On the role of the peroxisome in the metabolism of drugs and xenobiotics. Biochem Pharmacol1998; 56:667–673. DOI: 10.1016/S0006-2952(98)00116-6
8.
MastersC. Lipidic signaling and peroxisomal function. Subcell Biochem1998; 30:437–452.
9.
MastersCJ. Omega-3 fatty acids and the peroxisome. Mol Cell Biochem1996; 165:83–93.
10.
BroscheTPlattD. The biological significance of plasmalogens in defense against oxidative damage. Exp Gerontol1998; 33:363–369. DOI: 10.1016/S0531-5565(98)00014-X
11.
VamecqJLatruffeN. Medical significance of peroxisome proliferator actived receptors. Lancet1999; 354:141–148. DOI: 10.1016/S0140-6736(98)10364-1
12.
MangelsdorfDJEvansRM. The RXR heterodimers and orphan receptors. Cell1995; 83:841–850.
13.
JohannesCBStellatoRKFeldmanHA. Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: Longitudinal results from the Massachusetts Women's Health Study. J Clin Epidemiol1999; 52:95–103. DOI: 10.1016/S0895-4356(98)00144-9
14.
PalmerCNCausevicMWolfCR. Modulation of fatty acid signaling by cytochrome P450 mediated hydroxylation. Biochem Soc Trans1997; 25:1160–1165.
15.
AmesBNShigenageMKHagenTM. Oxidant antioxidants and the degenerative diseases of aging. Proc Natl Acad Sci USA1993; 90:7915–7922.
16.
HongJTGlauertHP. Stimulation of the DNA binding activity of AP-1 by the peroxisome proliferator ciprofibrate and eicosanoids in cultured rat hepatocytes. Toxicology1998; 131:99–107. DOI: 10.1016/S0300-483X(98)00121-8
17.
ZhouYCWaxmanDJ. Cross-talk between janus kinase signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-alpha (PPAR alpha) signaling pathways. Growth hormone inhibition of par alpha transcriptional activity mediated by stat 5b. J Biol Chem1999; 274:2672–2681. DOI: 10.1074/jbc.274.5.2672
18.
Colville-NashPRQureshiSSWillisD. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heme oxygenase 1. J Immunol1998; 161:978–984.
19.
GelmanLFuchartJCAuwerxJ. An update on the mechanisms of action of the peroxisome proliferator-activated (PPARs) and their roles in inflammation and cancer. Mol Life Sci1999; 55:932–943.
20.
HuangJTWelchJSRicoteM. Interleukin 4 dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature1999; 400:378–382. DOI: 10.1038/22572
21.
GelmanLFruchartJCAuwerxJ. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci1999; 55:932–943.
WahiiWBraissantODesvergneB. Peroxisome proliferator activated receptors: Transcriptional regulators of adipogenesis, lipid metabolism and more. Chem Biol1995; 2:261–266.
25.
WaxmanDJ. Role of metabolism in the activation of dehydroepiandrosterone as a peroxisome proliferator. J Endocrinol1996; 150:S129–S147.
26.
FanIQCattleyRCCortonJC. Tissue-specific induction of 17β-hydroxysteroid dehydrogenase type IV by peroxisome proliferator chemicals is dependent on the peroxisome proliferator-activated receptor a. J Endocrinol1998; 158:237–246.
27.
GonzalezFJPetersJMCattleyRC. Mechanism of action of the nongenotoxic peroxisome proliferators: Role of the peroxisome proliferator acted receptor alpha. J Natl Can Inst1998; 90:1702–1709.
28.
BravermanNLinPMoebiusFF. Mutations in the gene encoding 3β-hydroxsteroid-A8, A7-isomerase cause X-linked dominant Conradi-Hunermann syndrome. Nat Genet1999; 22:291–294. DOI: 10.1038/10357
29.
DerryJMJGormallyEMeansGD. Mutation in a A8, A7 sterol isomerase in the tattered mouse and X-linked dominant chondrodysplasia punctata. Nat Genet1999; 22:286–290. DOI: 10.1038/10350
30.
KelleyRI. RSH/Smith–Lemli–Opitz syndrome: Mutations and metabolic morphogenesis. Am J Hum Genet1998; 63:322–326. DOI: 10.1086/301987
31.
YoshizawaTHandaYUematsuY. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet1997; 16:391–396.
32.
JonesGStrugnellSADeLucaHF. Current understanding of the molecular actions of vitamin D. Physiol Rev1998; 78:1193–1231.
33.
PorterJAYoungKEBeachyPA. Cholesterol modification of hedgehog signaling proteins in animal development. Science1996; 274:255–259. DOI: 10.1126/science.274.5285.255
34.
FareseRVHerzJ. Cholesterol metabolism and embryogenesis. Trends Genet1998; 14:115–120. DOI: 10.1016/S0168-9525(97)01377-2
35.
PrueferDScaliaRLeferAM. Simvastatin inhibits leukocyteendothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol1999; 19:2894–2890.
36.
JamesNHGillJHBrindleR. Peroxisome proliferator (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis. Toxicol Lett1998; 28:102–103.
37.
KomuvesLHanleyKManM-Q. Regulation of keratinocyte growth and differentiation in hyperproliferative epidermal PPAR alpha activator restores tissue hemostasis. Invest Dermatol1999; 112:544.
HertzRBermanIKepplerD. Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome proliferator-activated receptor (PPAR). Eur J Biochem1996; 235:242–247.
HanleyKJiangYHeSS. Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPAR alpha. J Invest Dermatol1998; 110:368–375. DOI: 10.1046/j.1523-1747.1998.00139.x
42.
RivierMSafonovaILebrunP. Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Invest Dermatol1998; 111:1116–1121. DOI: 10.1046/j.1523-1747.1998.00439.x
43.
TomaszewskiKEMelnickRL. Vitro evidence for involvement of CoA thioesters in peroxisome. In proliferation and hypolipidemia. Biochem Biophys Acta1994; 1220:118–124.
44.
AarslandABergeRK. Peroxisome proliferating sulphur- and oxysubstituted fatty acid analogues are activated to acyl coenzyme A thioester. Biochem Pharmacol1991; 41:53–61.
45.
NestelPJ. Effects of omega-3 fatty acids on lipid metabolism. Annu Rev Nutr1990; 10:149–167.
46.
WoutersenRAAppelMJvan Garderen-HoetmerA. Dietary fat and carcinogenesis. Mutat Res1999; 443:111–127.
47.
EmamiSRizzoWBHanleyKP. Peroxisomal abnormality in fibroblasts from involved skin of CHILD syndrome. Arch Dermatol1992; 128:1213–1222.
48.
LawrenceJJSchlesingerAEKozlowskiK. Unusual radiographic manifestations of chondrodysplasia punctata. Skeletal Radiol1989; 18:15–19.
49.
PoynterMEDaynesRA. Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-β signaling, and reduces inflammatory cytokine production in aging. J Bio Chem1998; 273:32833–32841.
50.
WaxmanDJ. P450 gene induction by structurally diverse xenochemicals: Central role nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys1999; 369:11–23. DOI: 10.1006/abbi.1999. 1351
51.
de MoissacDZhengHKirshenbaumLA. Linkage of the BH14 domain of Bcl-2 and nuclear factor kappa B signaling pathway for suppression of apoptosis. J Biol Chem1999; 274:29505–29509. DOI: 10.1074/jbc.274.41.29505
HanleyKJiangYCrumrineD. Activation of the nuclear hormone receptors PPARα and FXR accelerate the development of the fetal epidermal permeability barrier. J Clin Invest1997; 100:705–721.
54.
CarrASamarasKThorisdottirA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: Cohort study. Lancet1999; 353:2093–2099. DOI: 10.1016/S0140-6736(98)08468-2
55.
GlorainMFranckhauser-VogelSRobinD. Glucocorticoids repress induction by thiazolidinediones, fibrates, and fatty acids of phosphoenolpyruvate carboxykinase gene expression in adipocytes. J Cell Biochem1998; 68:298–308. DOI: 10.1002/(SICI)1097-4644(19980301)68:3<298:AID-JCB2>3.3.CO;2-#.
56.
BarnesCJLeeM. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli in mouse model with aspirin. Gastroenterology1998; 114:873–877.
57.
BeginatoMJSkakowSLBaileyST. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator activated receptor gamma. J Biol Chem1998; 273:1855–1858. DOI: 10.1074/jbc.273.4.1855
58.
CaiYShleniusA-KAndersonK. Effects of acetylsalicylic acid on parameters related to peroxisome proliferation in mouse liver. Biochem Pharmacol1994; 47:2213–2219.
59.
GuytonKZGorospeMWangX. Age-related changes in activation of mitogen-activated protein kinase cascades by oxidative stress. J Invest Dermatol Symp Proc1998; 5:23–27.
60.
GilroyDWColville-NashPRChiversWJ. Inducible cyclo-oxygenase may have anti-inflammatory properties. Nat Med1999; 5:698–701. DOI: 10.1038/9550
61.
DuboisACryerB. The advent of highly selective inhibitors of cyclooxygenase—a review. Prostaglandins Other Lipid Mediat1998; 56:341–361.
62.
WenzelSE. New approaches to anti-inflammatory therapy for asthma. Am J Med1998; 104:287–300. DOI: 10.1016/S0002-9343(98)00031-X
63.
GreenspanPDFujimotoRAMarshallPJ. Carboxysubstituted cinnamides: A novel series of potent oral active LTB4 receptor antagonists. J Med Chem1999; 42:164–172. DOI: 10.1021/jm980540v
64.
ZhouYTWangZWHigaM. Reversing adipocyte differentiation: Implications for treatment of obesity. Proc Natl Acad Sci1999; 96:2391–2395.
MartinezM. Polyunsaturated fatty acids in the developing human brain, erythrocytes and plasma in peroxisomal disease: Therapeutic implications. J Inherit Metab Dis1995; 18:61–75.
67.
KellyKAGimbleJM. 1,25-Dihydroxyvitamin D3 inhibits adipocyte differentiation and gene expression in murine bone marrow stromal cell clones and primary cultures. Endocrinology1998; 139:2622–2628.
68.
RohdeCMManattMClagett-DameM. Vitamin A antagonizes the actions of vitamin D in rats. J Nutr1999; 129:2246–2250.
69.
ValmasedaACarmonaMCBarberaMJ. Opposite regulation of PPAR-alpha and -gamma gene expression by both their ligands and retinoic acid in brown adipocytes. Mol Cell Endocrinol1999; 154:101–109. DOI: 10.1016/S0303-7207(99)00081-7
70.
RanhardtTAKoozewskiNJOmdalJ. 1,25 Dihydroxyvitamin D(3) and 9-cis-retinoic acid are synergistic regulators of 24-hydroxylase activity in the rat, and 1,25 dihydroxyvitamin D(3) alters retinoic acid metabolism in vivo. Arch Biochem Biophys1999; 368:244–248. DOI: 10.1006/abbi.1999.1335
71.
SauratJH. Retinoids and psoriasis: Retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol1999; 41:S2–S6.
72.
FisherGJVoorheesJJ. Molecular mechanisms of photoaging and its prevention by retinoic acid: Ultraviolet irradiation induces MMP kinase signal transduction cascades that induce AP-1-regulated matrix metalloproteinases that degrade human skin in vivo. J Invest Dermatol Symp Proc1998; 3:61–68.
73.
KubotaTKoshisuzaKWilliamsonEA. Ligand for peroxisome proliferator activated receptor (troglitaxone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res1998; 19:925–931.
74.
EltstnerEMullerCKosthizukaK. Ligands for peroxiome proliferator activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in BNX mice. Proc Natl Acad Sci1998; 95:8806–8811.
75.
SarrafPMuellerESmithWM. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell1999; 3:799–804. DOI: 10.1016/S1097-2765(01)80012-5
76.
CampbellMJParkSUekatkoriicMR. Synergistic inhibition of prostate cancer cell lines by 19-nor hexafluoride, vitamin 3 analog, and antiactivator protein 1 retinoid. Br J Cancer1999; 79:101–107.
77.
ElstnerECampellMJMunkenR. Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate1999; 40:141–149. DOI: 10.1002/(SICI)1097-0045(19990801)40:3<141:AID-PROS1> 3.3.CO;2-3
78.
RosenfieldRLDeplewskiDKentsisA. Mechanisms of androgen induction of sebocyte differentiation. Dermatology1998; 196:43–46.
79.
StallmeyerBKampferHKolbN. The function of nitric oxide in wound repair: Inhibition of inducible nitric oxide synthase severely impairs wound re-epithelialization. J Invest Dermatol1999; 113:1090–1098. DOI: 10.1046/j.1523-1747.1999.00784.x
80.
SatoTTadokoroTSonodaT. Minoxidil increases 17-beta-hydroxysteroid dehydrogenase and 5-alpha-reductase activity of cultured human dermal papilla cells from balding scalp. J Dermatol Sci1999; 19:123–125. DOI: 10.1016/S0923-1811(98)00048-6
81.
BaumgartnerMRPoll-TheBTVerhoevenNM. Clinical approach to inherited peroxisomal disorders: A series of 27 patients. Ann Neurol1998; 44:720–730.
82.
MoserHWRaymondGV. Genetic peroxisomal disorder: Why, when, and how to test. Am Neurol Assoc1998; 44:713–715.
83.
MoserABKreiterNBezmanL. Plasma very long chain fatty acids, 3,000 peroxisome disease patients, and 29,000 controls. Ann Neurol1999; 45:100–110. DOI: 10.1002/1531-8249(199901)45:1 <100:AID-ART16>3.0.CO;2-U
